116 related articles for article (PubMed ID: 23920036)
21. Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
Ziemssen T; Tumani H; Sehr T; Thomas K; Paul F; Richter N; Samara E; Spiegelstein O; Sorani E; Bar-Ilan O; Mimrod D; Hayardeny L
J Neuroinflammation; 2017 Aug; 14(1):172. PubMed ID: 28859672
[TBL] [Abstract][Full Text] [Related]
22. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Aharoni R; Saada R; Eilam R; Hayardeny L; Sela M; Arnon R
J Neuroimmunol; 2012 Oct; 251(1-2):14-24. PubMed ID: 22749337
[TBL] [Abstract][Full Text] [Related]
23. Review of laquinimod and its therapeutic potential in multiple sclerosis.
Thöne J; Gold R
Expert Opin Pharmacother; 2013 Dec; 14(18):2545-52. PubMed ID: 24215556
[TBL] [Abstract][Full Text] [Related]
24. Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.
Dobson L; Träger U; Farmer R; Hayardeny L; Loupe P; Hayden MR; Tabrizi SJ
J Neurochem; 2016 Jun; 137(5):782-94. PubMed ID: 26823290
[TBL] [Abstract][Full Text] [Related]
25. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
[TBL] [Abstract][Full Text] [Related]
26. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
27. Laquinimod in multiple sclerosis.
Giacomini PS; Bar-Or A
Clin Immunol; 2012 Jan; 142(1):38-43. PubMed ID: 21450529
[TBL] [Abstract][Full Text] [Related]
28. Regulatory effects of cytokines and cyclosporine A on peripheral blood mononuclear cells from stable multiple sclerosis patients.
Guillen C; Prieto A; Alvarez-Cermeño JC; de la Piedra M; Gimeno A; Alvarez-Mon M
Immunopharmacol Immunotoxicol; 1999 Aug; 21(3):527-49. PubMed ID: 10466078
[TBL] [Abstract][Full Text] [Related]
29. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
30. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients.
Sternberg Z; Chadha K; Lieberman A; Hojnacki D; Drake A; Zamboni P; Rocco P; Grazioli E; Weinstock-Guttman B; Munschauer F
J Neuroimmunol; 2008 Dec; 205(1-2):142-7. PubMed ID: 18926575
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.
Runström A; Leanderson T; Ohlsson L; Axelsson B
J Neuroimmunol; 2006 Apr; 173(1-2):69-78. PubMed ID: 16472873
[TBL] [Abstract][Full Text] [Related]
32. The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials.
Rouhi F; Mohammadpour Z; Noureini SK; Abbastabar H; Harirchian MH; Bitarafan S
Eur J Clin Pharmacol; 2020 May; 76(5):611-622. PubMed ID: 32020320
[TBL] [Abstract][Full Text] [Related]
33. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.
Pentón-Rol G; Cervantes-Llanos M; Cabrera-Gómez JA; Alonso-Ramírez R; Valenzuela-Silva C; Rodríguez-Lara R; Montero-Casimiro E; Bello-Rivero I; López-Saura P
Int Immunopharmacol; 2008 Jun; 8(6):881-6. PubMed ID: 18442793
[TBL] [Abstract][Full Text] [Related]
34. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis.
Rolland A; Jouvin-Marche E; Saresella M; Ferrante P; Cavaretta R; Créange A; Marche P; Perron H
J Neuroimmunol; 2005 Mar; 160(1-2):195-203. PubMed ID: 15710473
[TBL] [Abstract][Full Text] [Related]
35. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A.
Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V
Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Sellebjerg F; Hesse D; Limborg S; Lund H; Søndergaard HB; Krakauer M; Sørensen PS
Mult Scler; 2013 Feb; 19(2):179-87. PubMed ID: 22653658
[TBL] [Abstract][Full Text] [Related]
37. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
[TBL] [Abstract][Full Text] [Related]
38. Oral laquinimod for multiple sclerosis: beyond the anti-inflammatory effect.
Tur C
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):832. PubMed ID: 24046393
[No Abstract] [Full Text] [Related]
39. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
[TBL] [Abstract][Full Text] [Related]
40. Treatment of multiple sclerosis with the pregnancy hormone estriol.
Sicotte NL; Liva SM; Klutch R; Pfeiffer P; Bouvier S; Odesa S; Wu TC; Voskuhl RR
Ann Neurol; 2002 Oct; 52(4):421-8. PubMed ID: 12325070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
